NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Portfolio Pulse from
Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against Intellia Therapeutics (NTLA) alleging the company made false or misleading statements about its drug NTLA-3001's development and viability between July 30, 2024 and January 8, 2025. The lawsuit claims Intellia misrepresented the potential of viral-based editing programs and the drug's research and development capabilities.
April 03, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The class action lawsuit could negatively impact Intellia's stock price by raising concerns about the company's transparency and drug development claims.
The lawsuit alleges serious misrepresentations about NTLA-3001's development, which could damage investor trust, potentially leading to stock price decline. The specific claims about misleading statements and drug viability create significant legal and reputational risk.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100